Elixir Pharmaceuticals, of Cambridge, Mass., said it has raised $46 million in a third round of funding. The financing includes $31 million in equity funding and $15 million in venture debt placement from Hercules.
The company is developing treatments for a number of diseases, mostly age-related. Here is a brief description of its technology.
The funding came from MPM Capital, Oxford BioScience Partners, ARCH Venture Partners, CDIB Ventures, JAFCO and YFY Biotech Management Company, among others.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.
